A-share IPO | Radiotherapy positioning device leader Kleredi (920072.BJ) starts IPO with collaboration with Shanghai United Imaging Healthcare and Siemens.

On June 15th, Koleridi (920072.BJ) started its IPO subscription, with an issue price of 15.62 yuan per share and a subscription limit of 266,400 shares. The price-to-earnings ratio is 19.62 times, and it belongs to the Beijing Stock Exchange, with China Galaxy Securities as its sponsor. According to the prospectus, Koleridi is a provider of complementary medical equipment solutions in the field of radiation therapy and rehabilitation therapy. Its main business is the research, development, production, and sales of radiation therapy positioning devices in tumor radiation therapy, as well as rehabilitation auxiliary equipment in rehabilitation therapy. As of the end of the reporting period, the company has obtained a total of 148 patents (145 domestic patents and 3 foreign patents), including 47 invention patents (44 domestic invention patents and 3 foreign invention patents), and has been granted registration for 2 class III and 5 class II medical device products. In the field of radiation therapy, the company has become one of the leading companies in the global radiation therapy positioning industry. According to Frost & Sullivan's industry research report, based on sales, the company ranked third globally in the position fixing product submarket with a market share of 7.0% in 2023, and ranked first domestically with a market share of 42.5%. The company is also one of the few manufacturers in the industry that have the production capabilities for both position fixing products and radiation therapy positioning systems. Koleridi's radiation therapy positioning devices have been recognized by top oncology treatment institutions both domestically and internationally. During the reporting period, its end customers included 6 out of the top 10 global oncology treatment institutions and 8 out of the top 10 national oncology specialty hospitals. Additionally, the company has reached various degrees of horizontal cooperation with radiation therapy equipment and supporting software manufacturers such as Shanghai United Imaging Healthcare, Xiamen Manteia Company, Siemens, GE Healthcare, and Philips. In terms of finances, for the fiscal years 2023, 2024, and 2025, the company achieved operating revenues of approximately 238 million yuan, 285 million yuan, and 315 million yuan respectively; during the same period, net profits were approximately 59.91 million yuan, 67.21 million yuan, and 64.03 million yuan respectively.